---
title: "Zelgen: Clinical data for ZG006 and ZG005 released at the 28th Annual Academic Conference of the Chinese Society of Clinical Oncology (CSCO)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/256866335.md"
description: "Zelgen announced that it will present clinical research data for its new drugs ZG006 and ZG005 at the 28th Annual Academic Conference of the Chinese Society of Clinical Oncology (CSCO) from September 10 to 14, 2025. The Phase II clinical study of ZG006 targets patients with refractory advanced small cell lung cancer, while ZG005 is undergoing Phase I/II studies in first-line advanced neuroendocrine cancer patients"
datetime: "2025-09-11T07:50:17.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/256866335.md)
  - [en](https://longbridge.com/en/news/256866335.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/256866335.md)
---

# Zelgen: Clinical data for ZG006 and ZG005 released at the 28th Annual Academic Conference of the Chinese Society of Clinical Oncology (CSCO)

According to the Zhitong Finance APP, Zelgen (688266.SH) announced that the clinical research data and latest progress of its independently developed new drugs Alveltamig (code: ZG006) and Nilvanstomig (code: ZG005) will be presented at the 28th Annual Academic Conference of the Chinese Society of Clinical Oncology (CSCO) to be held from September 10 to 14, 2025.

The Phase II dose optimization clinical study of ZG006 monotherapy in patients with refractory advanced small cell lung cancer (SCLC) (ZG006-002) has been selected for an oral presentation in the lung cancer session of this annual meeting. As of May 12, 2025, a total of 60 patients with third-line or higher SCLC were randomly assigned in a 1:1 ratio to receive either ZG006 10mg Q2W or 30mg Q2W treatment and included in the analysis. The initial dosing was a 1mg titration dose. The baseline characteristics of the two groups of patients were generally balanced.

The data and latest progress of the Phase I/II clinical study (ZG005-004) on the safety, pharmacokinetic characteristics, and preliminary efficacy of ZG005 in combination with Etoposide and Cisplatin (EP) in first-line advanced neuroendocrine carcinoma patients: As of August 21, 2025, a total of 84 patients were included. 92.9% of patients had a Ki-67 proliferation index ≥55%, and 64.3% of patients had liver metastasis. The most common primary tumor site was the gastrointestinal tract, accounting for 36.9%

### Related Stocks

- [688266.CN](https://longbridge.com/en/quote/688266.CN.md)

## Related News & Research

- [Just 4% of fund managers see a hard landing - BofA survey](https://longbridge.com/en/news/286866256.md)
- [05:20 ETThrough the America's Most Artistic Kid Competition, Colossal Raises $1.6 Million While Celebrating the Next Gen of Creative Visionaries](https://longbridge.com/en/news/287037755.md)
- [09:06 ETHarmony Comes to the Massachusetts State House as The Platters® Prepare Their Musical Love Letter to the World](https://longbridge.com/en/news/286918739.md)
- [Lula ahead of Bolsonaro in Brazil presidential vote poll](https://longbridge.com/en/news/286896793.md)
- [ZAWYA: Sahm App exceeds 2mln users, marking a new milestone in its growth journey](https://longbridge.com/en/news/287084031.md)